Bicara Therapeutics (NASDAQ:BCAX) COO Ryan Cohlhepp Sells 18,750 Shares

Bicara Therapeutics Inc. (NASDAQ:BCAX) COO Ryan Cohlhepp sold 18,750 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $27.98, for a total value of $524,625.00. Following the completion of the transaction, the chief operating officer directly owned 181,641 shares of the company’s stock, valued at approximately $5,082,315.18. This trade represents a 9.36% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ryan Cohlhepp also recently made the following trade(s):

• On Thursday, July 9th, Ryan Cohlhepp sold 536 shares of Bicara Therapeutics stock. The shares were sold at an average price of $29.00, for a total transaction of $15,544.00.
• On Wednesday, July 8th, Ryan Cohlhepp sold 28,214 shares of Bicara Therapeutics stock. The stock was sold at an average price of $28.98, for a total transaction of $817,641.72.
• On Friday, May 15th, Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock. The shares were sold at an average price of $20.29, for a total transaction of $253,625.00.

Bicara Therapeutics Stock Up 3.7%

BCAX opened at $24.63 on Thursday. The stock has a market capitalization of $1.62 billion, a price-to-earnings ratio of -7.95 and a beta of -0.75. The firm has a 50 day moving average price of $26.00 and a 200-day moving average price of $21.74. Bicara Therapeutics Inc. has a twelve month low of $10.30 and a twelve month high of $30.99.

Bicara Therapeutics (NASDAQ:BCAX) last issued its earnings results on Tuesday, August 11th. The company reported ($0.82) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.82). As a group, analysts expect that Bicara Therapeutics Inc. will post -3.42 earnings per share for the current year.

Key Stories Impacting Bicara Therapeutics

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: Bicara reported second-quarter adjusted earnings of -$0.82 per share, in line with expectations, while investors focused on continued progress in its pivotal cancer trial. Enrollment remains on track for 2026, an important milestone for the company’s lead program. Bicara Therapeutics stock gains as pivotal trial enrollment advances
• Positive Sentiment: Analyst sentiment improved after the results. BTIG Research raised its price target from $28 to $39 and maintained a Buy rating, implying substantial potential upside based on the company’s clinical outlook. Other analysts also increased their forecasts after the quarterly report. Bicara Therapeutics analysts raise forecasts
• Positive Sentiment: Wedbush said the company’s cancer study remains on track for 2026 enrollment, reinforcing expectations that Bicara could reach significant clinical catalysts over the coming months. Bicara Therapeutics cancer study remains on track
• Neutral Sentiment: Analyst views remain mixed. Wells Fargo raised its target from $16 to $23 but retained an Equal Weight rating, placing its target below the stock’s recent trading level. Bicara also announced strategic leadership transitions as it moves into its next phase of execution. Wells Fargo price-target update
• Negative Sentiment: CEO Claire Mazumdar, COO Ryan Cohlhepp and CFO Ivan Hyep collectively sold 41,250 shares for approximately $1.15 million. The transactions were conducted under pre-arranged Rule 10b5-1 plans, and each executive retained a sizable position, reducing—but not eliminating—the negative signal from insider selling. Bicara insider transaction filings

Analyst Ratings Changes

Several analysts recently commented on BCAX shares. Mizuho lifted their price objective on Bicara Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Wednesday. Morgan Stanley increased their target price on Bicara Therapeutics from $37.00 to $39.00 and gave the company an “overweight” rating in a report on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Monday, July 6th. Cantor Fitzgerald restated an “overweight” rating on shares of Bicara Therapeutics in a research note on Wednesday, May 27th. Finally, BTIG Research upped their price target on shares of Bicara Therapeutics from $28.00 to $39.00 and gave the company a “buy” rating in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $32.73.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Candriam S.C.A. purchased a new stake in shares of Bicara Therapeutics in the 1st quarter worth $4,750,000. UBS Group AG lifted its position in Bicara Therapeutics by 97.4% during the fourth quarter. UBS Group AG now owns 192,191 shares of the company’s stock valued at $3,235,000 after purchasing an additional 94,829 shares in the last quarter. Janus Henderson Group PLC lifted its position in Bicara Therapeutics by 26.2% during the first quarter. Janus Henderson Group PLC now owns 3,339,218 shares of the company’s stock valued at $66,350,000 after purchasing an additional 692,933 shares in the last quarter. Rock Springs Capital Management LP grew its holdings in Bicara Therapeutics by 14.0% during the first quarter. Rock Springs Capital Management LP now owns 489,095 shares of the company’s stock valued at $9,728,000 after purchasing an additional 60,000 shares during the period. Finally, Orbimed Advisors LLC grew its holdings in Bicara Therapeutics by 219.1% during the first quarter. Orbimed Advisors LLC now owns 667,300 shares of the company’s stock valued at $13,273,000 after purchasing an additional 458,200 shares during the period.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.